US Jury Awards $56 Million in Damages Against Cytek Biosciences in Patent Case

Key Facts

1A US jury ruled in favor of Cytek on three out of four patent infringement claims brought by Beckman Coulter.

2The jury awarded $56 million in damages against Cytek for infringing one patent claim under the doctrine of equivalents.

In a move highlighting the legal complexities within the biotech sector, a US jury has ordered Cytek Biosciences to pay significant damages following a patent dispute. The jury in the District of Delaware ruled that Cytek infringed on one patent claim brought by Beckman Coulter under the doctrine of equivalents, while finding Cytek non-infringing on three other patent claims. Cytek has indicated its intention to challenge the remaining finding through post-trial motions and potential appeals.

The $56 million damages award is comprised of $20 million in lost profits and $36 million in royalties, representing a notable financial burden for the cell analysis solutions company. According to reports, the verdict stems from litigation regarding specialized cell analysis technology used in Cytek's core platforms. While the company successfully defended three of the four claims, the scale of the damages for the single infringement remains a primary concern for stakeholders, per market context.

Regarding market performance, updated price levels for Cytek Biosciences are currently unavailable according to market data (as of close August 21, 2026). Investors should closely monitor upcoming legal filings related to the appeal process which could mitigate or solidify these liabilities. Additionally, broader market sentiment may be influenced by upcoming economic catalysts, such as the US Building Permits data scheduled for release on August 18.

Sources:

globenewswire.com